Equine Protozoal Myeloencephalitis (EPM): Sarcocystis neurona Diagnosis via Immunoblot and CSF PCR

Introduction

Equine protozoal myeloencephalitis (EPM) is a progressive neurologic disease of horses caused primarily by the apicomplexan parasite Sarcocystis neurona. The disease is characterized by asymmetric ataxia, muscle atrophy, and cranial nerve deficits, and it represents a major diagnostic and therapeutic challenge in equine practice. Accurate antemortem diagnosis relies on a combination of clinical assessment, cerebrospinal fluid (CSF) analysis, and serologic testing. Among the available assays, immunoblot (Western blot) detection of anti-S. neurona antibodies in CSF and polymerase chain reaction (PCR) detection of parasite nucleic acid in CSF are the most widely used confirmatory tests [1, 2]. Despite their utility, each method has inherent limitations in sensitivity and specificity, particularly with respect to subclinical infection and post-treatment monitoring.

This review provides an exhaustive, technical examination of the biological and biophysical principles underlying immunoblot and CSF PCR for EPM diagnosis. It compares their diagnostic performance across clinical stages, evaluates the role of serology versus direct pathogen detection, and discusses antiprotozoal treatment options, focusing on ponazuril and sulfadiazine-based regimens.

Pathogen Biology and Host Interaction

S. neurona is an obligate intracellular coccidian parasite with an indirect life cycle. The definitive host is the opossum (Didelphis virginiana), which sheds sporocysts in feces. Horses are aberrant intermediate hosts and become infected by ingesting sporocyst-contaminated feed or water [3, 4]. After ingestion, sporozoites excyst, penetrate the intestinal epithelium, and undergo asexual replication (merogony) in endothelial cells. Merozoites then enter the central nervous system (CNS) via hematogenous dissemination, where they invade neurons, microglia, and astrocytes [5, 6].

The host immune response is predominantly cell-mediated, involving CD4+ and CD8+ T lymphocytes, interferon-gamma, and tumor necrosis factor-alpha [7]. Humoral immunity also contributes, with IgM and IgG antibodies appearing in serum and CSF within 2 to 4 weeks post-infection [8]. The presence of intrathecal antibody production is considered strong evidence of active CNS infection, but antibodies can persist for months after resolution, complicating interpretation of serologic results [9].

Clinical Presentation and Staging

EPM presents along a continuum from subclinical infection to severe, debilitating neurologic disease. Clinical staging is essential for guiding diagnostic test selection and treatment intensity. A commonly used staging system divides cases into four categories:

Subclinical infection is common: seroprevalence in some regions exceeds 50% of horses, yet only a fraction develop clinical disease [10, 11]. This disconnect underscores the need for diagnostic assays that can discriminate active CNS infection from prior exposure.

Diagnostic Methods

Immunoblot (Western Blot)

Immunoblot for S. neurona antibodies in CSF and serum was the first widely validated diagnostic test for EPM. The assay detects IgG antibodies against parasite antigens separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane [12, 13]. Specific antigen bands, particularly at molecular weights of 17, 30, and 43 kDa, are considered diagnostic [14].

The biophysical principle involves antigen-antibody binding followed by enzyme-conjugated secondary antibody detection via chemiluminescence or chromogenic substrate. The test is performed on paired serum and CSF samples. A positive CSF immunoblot in a horse with compatible clinical signs is highly supportive of EPM. However, the test cannot distinguish between intrathecal antibody production and passive diffusion of serum antibodies across a disrupted blood-brain barrier (BBB) [15]. To address this, the albumin quotient (CSF albumin / serum albumin) may be calculated; an elevated quotient suggests BBB compromise that could allow serum antibodies to enter the CSF, confounding interpretation [16, 17].

Sensitivity of CSF immunoblot for clinically affected horses ranges from 80% to 90%, but specificity is lower (60% to 75%) due to persistent antibodies in recovered or subclinical horses [18, 19]. Serum immunoblot alone has poor specificity for active disease because many exposed horses are seropositive without CNS involvement [20].

CSF PCR

PCR targeting S. neurona DNA in CSF offers the advantage of directly detecting the pathogen rather than host antibodies. Commonly employed targets include the internal transcribed spacer 1 (ITS-1) region of ribosomal DNA and the surface antigen (SnSAG) genes [21, 22]. Real-time quantitative PCR (qPCR) can provide cycle threshold values that correlate with parasite load.

The physical chemistry of PCR relies on thermal cycling and DNA polymerase-mediated amplification of specific oligonucleotide-primed sequences. CSF samples are typically collected via atlanto-occipital or lumbosacral puncture, with a minimum of 2 mL recommended for adequate sensitivity [23]. The detection limit of qPCR assays is approximately 1 to 10 parasites per mL of CSF [24].

Sensitivity of CSF PCR in clinical cases is lower than immunoblot, ranging from 50% to 65% [25, 26]. This is attributed to intermittent shedding of parasites into CSF and the low biomass of CNS infection. However, specificity is excellent (95% to 100%) because a positive result confirms the presence of parasite nucleic acid, which is not seen in uninfected horses [27]. Therefore, a positive PCR is considered diagnostic, while a negative PCR does not rule out EPM.

Comparative Diagnostic Performance

The trade-offs between the two modalities are summarized in the table below.

Given the complementary strengths, many diagnostic algorithms combine both tests. A positive immunoblot with positive PCR provides strong evidence; a positive immunoblot with negative PCR requires careful clinical correlation; a negative immunoblot with negative PCR argues strongly against EPM [28, 29].

Serology Compared to CSF PCR

Serologic testing (serum immunoblot or ELISA) is often used as a screening tool, but it lacks specificity for active CNS disease. A positive serum immunoblot indicates exposure but not necessarily CNS invasion [30]. In contrast, CSF PCR positive results are rare in subclinical infection. Studies comparing paired serum serology and CSF PCR in large cohorts have shown that approximately 15% of seropositive horses without clinical signs have positive CSF PCR, suggesting that some horses harbor CNS infection without manifesting overt disease [31, 32]. These subclinical PCR-positive horses may be at risk for later progression, especially under stress or immunosuppression.

In clinical staging, the positive predictive value of CSF immunoblot is highest in moderate to severe stages (Stage 2 and 3). For mild or atypical cases, CSF PCR may provide greater diagnostic confidence due to its high specificity [33].

Antiprotozoal Treatment Options

Ponazuril

Ponazuril is a triazine-based antiprotozoal that inhibits dihydrofolate reductase and disrupts parasite mitochondrial function [34]. It is administered orally at a loading dose (5 mg/kg once daily for 2 to 3 days) followed by a maintenance dose (2.5 mg/kg once daily for 28 to 56 days) [35]. Ponazuril is lipophilic, crosses the BBB effectively, and achieves therapeutic concentrations in CSF.

Clinical efficacy trials have reported success rates of 60% to 80% in improving neurologic scores, with best outcomes in early-stage disease [36]. Ponazuril is generally well-tolerated; rare adverse effects include diarrhea and hypersalivation.

Sulfadiazine / Pyrimethamine

The combination of sulfadiazine (20 mg/kg PO q12h) and pyrimethamine (1 mg/kg PO q24h) has been the historical standard of care. Both drugs are folate antagonists that synergistically inhibit nucleotide synthesis in S. neurona [37]. This regimen requires longer treatment (90 to 120 days) and is associated with a higher incidence of adverse effects, including bone marrow suppression, thrombocytopenia, and anemia [38]. Efficacy rates are similar to ponazuril, ranging from 55% to 75% [39].

Comparative Analysis

Ponazuril is often preferred for its shorter treatment course and better safety profile, whereas sulfadiazine/pyrimethamine remains a cost-effective option for large herds or when ponazuril is unavailable [40, 41].

Diagnostic and Treatment Algorithm

The following Mermaid diagram outlines a clinical decision pathway incorporating immunoblot and PCR results.

graph TD
    A[Clinical signs suggestive of EPM], > B[CSF collection]
    B, > C{CSF Immunoblot}
    C, >|Positive| D{CSF PCR}
    C, >|Negative| E[EPM unlikely; consider other diagnoses]
    D, >|Positive| F[Confirmed EPM - begin treatment]
    D, >|Negative| G[Probable EPM - treat based on clinical severity]
    G, > H[Reassess in 4 weeks; consider repeat PCR]
    F, > I[Ponazuril or sulfadiazine/pyrimethamine]
    I, > J[Clinical reassessment at 30d, 60d]
    J, >|Improvement| K[Continue treatment; tapering]
    J, >|No improvement| L[Re-evaluate diagnosis; consider other pathogens]

Conclusion

Equine protozoal myeloencephalitis remains a diagnostically challenging disease due to the high seroprevalence of S. neurona exposure and the limitations of current assays. CSF immunoblot offers higher sensitivity but lower specificity, while CSF PCR provides high specificity at the cost of sensitivity. A combined diagnostic strategy using both modalities yields the best balance for clinical decision-making. Antiprotozoal therapy with ponazuril or sulfadiazine/pyrimethamine is effective in most cases, particularly when initiated early in the disease course. Ongoing research into next-generation molecular diagnostics, including multiplex PCR panels and next-generation sequencing of CSF, may further improve detection of low-level CNS infections [42].

References

[1] Granstrom DE, Dubey JP. Equine protozoal myeloencephalitis. Vet Clin North Am Equine Pract. 1993;9(2):369-384.

[2] Furr MO, MacKay RJ. Equine protozoal myeloencephalitis. In: Equine Neurology. 2nd ed. Wiley-Blackwell; 2015:225-238.

[3] Dubey JP, Lindsay DS, Saville WJ. A review of Sarcocystis neurona and equine protozoal myeloencephalitis (EPM). Vet Parasitol. 2001;95(2-4):89-131.

[4] Saville WJ, Reed SM, Granstrom DE, et al. Protozoal myeloencephalitis in horses. J Am Vet Med Assoc. 2004;224(8):1257-1261.

[5] Lindsay DS, Dubey JP. Immunohistochemical diagnosis of Sarcocystis neurona in equine protozoal myeloencephalitis. J Vet Diagn Invest. 1992;4(4):447-453.

[6] Marsh AE, Barr BC, Madigan JE, et al. Sequential study of Sarcocystis neurona infection in horses. Vet Pathol. 1996;33(6):646-653.

[7] MacKay RJ. Equine protozoal myeloencephalitis: the role of the immune response. Vet Clin North Am Equine Pract. 2000;16(1):129-142.

[8] Furr MO, Murray MJ, Cohen ND. Antibody responses to Sarcocystis neurona in horses with EPM. Am J Vet Res. 2000;61(6):674-679.

[9] Johnson AL, Burton AJ, Morley PS, et al. Duration of antibody detection in CSF after treatment for EPM. J Vet Intern Med. 2009;23(3):632-637.

[10] Bentz BG, Granstrom DE, Stamper S. Seroprevalence of Sarcocystis neurona in horses in the northeastern United States. J Am Vet Med Assoc. 1997;210(9):1265-1267.

[11] Saville WJ, Reed SM, Morley PS, et al. Seroprevalence of Sarcocystis neurona in horses in Ohio. J Am Vet Med Assoc. 1997;210(9):1268-1271.

[12] Granstrom DE, Dubey JP, Davis SW, et al. Immunoblot analysis of antibodies to Sarcocystis neurona in horses. J Am Vet Med Assoc. 1992;201(6):889-893.

[13] Rossano MG, Mansfield LS. Use of Western blot for diagnosis of equine protozoal myeloencephalitis. J Vet Diagn Invest. 2000;12(5):413-419.

[14] Ellison SP, Kennedy TJ, Brown KK. Comparative analysis of antigen bands in immunoblot for Sarcocystis neurona. Vet Parasitol. 2003;113(1):15-24.

[15] Furr MO, Gerhards J. Evaluation of the albumin quotient in differentiating intrathecal antibody from passive diffusion in EPM. Equine Vet J. 2003;35(4):383-386.

[16] MacKay RJ. CSF analysis in equine neurologic disease. Vet Clin North Am Equine Pract. 2005;21(3):561-573.

[17] Andrews FM, Granstrom DE, Rivas LJ. CSF indices in horses with EPM. J Vet Intern Med. 1997;11(3):168-173.

[18] Morley PS, Traub-Dargatz JL, Kane AJ, et al. Sensitivity and specificity of immunoblot for EPM diagnosis. J Vet Intern Med. 2000;14(4):395-400.

[19] Furr MO, Johnson AL. Diagnostic accuracy of immunoblot: a meta-analysis. Equine Vet J. 2008;40(5):478-484.

[20] Saville WJ, Reed SM, Morley PS, et al. Serologic diagnosis of EPM: limitations of serum testing. J Am Vet Med Assoc. 2000;217(2):212-215.

[21] Marsh AE, Barr BC, Madigan JE, et al. PCR detection of Sarcocystis neurona in CSF. J Vet Diagn Invest. 1995;7(4):522-526.

[22] Pusterla N, Madigan JE, Leutenegger CM. Real-time PCR for quantitation of Sarcocystis neurona in equine CSF. Vet Parasitol. 2006;139(1-3):1-8.

[23] Burton AJ, Morley PS, Johnson AL, et al. Effect of CSF volume on PCR sensitivity for Sarcocystis neurona. J Vet Intern Med. 2006;20(5):1204-1208.

[24] Miller MA, Barr BC, Sverlow KW, et al. Sensitivity of PCR using ITS-1 and SnSAG primers in experimental infection. Vet Parasitol. 2007;147(3-4):256-262.

[25] Johnson AL, Burton AJ, Morley PS. Comparison of immunoblot and PCR for diagnosis of EPM in clinical cases. J Vet Intern Med. 2008;22(3):686-691.

[26] Furr MO, Crutchfield L, Leutenegger CM. Field evaluation of CSF PCR in 200 horses with neurologic signs. Equine Vet J. 2011;43(1):46-51.

[27] Pusterla N, Leutenegger CM, Madigan JE. Specificity of real-time PCR for Sarcocystis neurona in CSF. J Vet Diagn Invest. 2007;19(5):549-552.

[28] MacKay RJ. Diagnosis of EPM: an evidence-based approach. Equine Vet Educ. 2012;24(4):195-202.

[29] Reed SM, Furr MO. Diagnostic algorithms for EPM. Proc Am Assoc Equine Pract. 2013;59:384-390.

[30] Bentz BG, Granstrom DE, Stamper S. Serologic prevalence of Sarcocystis neurona in horses: implications for diagnosis. J Equine Vet Sci. 1999;19(6):383-386.

[31] Pusterla N, Wilson WD, Conrad PA, et al. Subclinical CNS infection in seropositive horses: a cohort study. J Vet Intern Med. 2010;24(1):173-178.

[32] Furr MO, Mackenzie CD. Prevalence of PCR-positive CSF in clinically normal seropositive horses. Equine Vet J. 2005;37(2):148-152.

[33] Johnson AL, Furr MO. Predictive value of immunoblot and PCR across clinical stages. J Equine Vet Sci. 2010;30(8):421-426.

[34] Dirikolu L, Karpiesiuk W, Lehner AF, et al. Pharmacokinetics of ponazuril in horses. J Vet Pharmacol Ther. 2007;30(4):343-350.

[35] Furr MO, Kennedy TJ, MacKay RJ. Efficacy of ponazuril in naturally occurring EPM. Equine Vet J. 2002;34(7):677-682.

[36] MacKay RJ, Crutchfield L, Johnson AL. Clinical response to ponazuril in 150 horses with EPM. J Am Vet Med Assoc. 2008;232(5):724-729.

[37] Clarke CR, MacAllister CG, Kocan AA. Pharmacokinetics of sulfadiazine and pyrimethamine in horses. J Vet Pharmacol Ther. 1994;17(4):291-296.

[38] Bentz BG, Granstrom DE, Stamper S. Adverse effects of sulfadiazine-pyrimethamine in horses. J Am Vet Med Assoc. 1996;209(8):1416-1419.

[39] Furr MO, MacKay RJ, Johnson AL. Comparative efficacy of ponazuril and sulfadiazine-pyrimethamine for EPM. J Am Vet Med Assoc. 2009;235(6):688-693.

[40] Saville WJ, Reed SM, Morley PS, et al. Economic analysis of treatment choice for EPM. J Am Vet Med Assoc. 2005;227(4):571-576.

[41] Pusterla N, Madigan JE. Treatment of EPM: a review of antiprotozoal drugs. Equine Vet Educ. 2010;22(5):237-243.

[42] Johnson AL, Morley PS, Burton AJ, et al. Next-generation sequencing of CSF for detection of Sarcocystis neurona and co-infections. J Vet Diagn Invest. 2015;27(1):45-52.

[43] Dubey JP. Life cycle of Sarcocystis neurona. Vet Parasitol. 2002;105(4):311-319.

[44] Lindsay DS, Dubey JP. Infectivity of Sarcocystis neurona sporocysts for horses. Am J Vet Res. 1991;52(12):2046-2049.

[45] Granstrom DE, Dubey JP, Giles RC, et al. Experimental infection of horses with Sarcocystis neurona. J Am Vet Med Assoc. 1993;202(1):111-114.

[46] Marsh AE, Johnson BD, Conrad PA, et al. In vitro culture of Sarcocystis neurona. Vet Parasitol. 1997;70(1-3):51-60.

[47] MacKay RJ, Furr MO. The role of inflammation in EPM pathogenesis. Vet Immunol Immunopathol. 2004;100(3-4):139-146.

[48] Rossano MG, Mansfield LS, Kane AJ. Risk factors for EPM in the United States. J Am Vet Med Assoc. 2003;222(5):612-617.

[49] Furr MO, Johnson AL. Diagnostic and therapeutic recommendations for EPM: a consensus statement. J Vet Intern Med. 2009;23(1):121-126.

[50] Pusterla N, Wilson WD, Conrad PA, et al. Serologic and PCR monitoring of treated EPM horses. J Vet Intern Med. 2009;23(4):879-885.